Cellebrite DI Ltd. (NASDAQ:CLBT – Get Free Report) CRO Marcus Jewell sold 9,928 shares of the business’s stock in a transaction dated Tuesday, November 17th. The shares were sold at an average price of $10.66, for a total transaction of $105,832.48. Following the completion of the transaction, the executive owned 404,345 shares in the company, valued at $4,310,317.70. The trade was a 2.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Marcus Jewell also recently made the following trade(s):
- On Monday, November 16th, Marcus Jewell sold 12,462 shares of Cellebrite DI stock. The shares were sold at an average price of $11.55, for a total transaction of $143,936.10.
- On Thursday, November 12th, Marcus Jewell sold 393 shares of Cellebrite DI stock. The stock was sold at an average price of $13.31, for a total transaction of $5,230.83.
- On Friday, August 21st, Marcus Jewell sold 12,562 shares of Cellebrite DI stock. The stock was sold at an average price of $11.24, for a total transaction of $141,196.88.
Cellebrite DI Stock Performance
CLBT stock opened at $11.16 on Thursday. The firm has a market cap of $2.78 billion, a PE ratio of 32.27, a PEG ratio of 1.35 and a beta of 1.06. The firm’s 50 day moving average price is $11.57 and its 200-day moving average price is $13.15. Cellebrite DI Ltd. has a one year low of $9.58 and a one year high of $19.39.
Analysts Set New Price Targets
CLBT has been the subject of several analyst reports. DA Davidson reiterated a “buy” rating and issued a $15.00 price objective on shares of Cellebrite DI in a research report on Tuesday, September 15th. Lake Street Capital reduced their target price on Cellebrite DI from $21.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, August 14th. Weiss Ratings raised Cellebrite DI from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, November 13th. JPMorgan Chase & Co. lowered their price target on Cellebrite DI from $16.00 to $15.00 and set an “overweight” rating for the company in a report on Friday, November 13th. Finally, Needham & Company LLC raised their price objective on Cellebrite DI from $12.50 to $14.00 and gave the stock a “buy” rating in a research report on Thursday, November 12th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $14.75.
View Our Latest Report on CLBT
Institutional Investors Weigh In On Cellebrite DI
Institutional investors and hedge funds have recently made changes to their positions in the stock. Nine Ten Capital Management LLC lifted its holdings in shares of Cellebrite DI by 19.8% in the 2nd quarter. Nine Ten Capital Management LLC now owns 4,126,808 shares of the company’s stock worth $60,251,000 after acquiring an additional 682,933 shares during the last quarter. Wellington Management Group LLP boosted its position in shares of Cellebrite DI by 93.7% during the 2nd quarter. Wellington Management Group LLP now owns 3,049,904 shares of the company’s stock worth $44,529,000 after purchasing an additional 1,475,579 shares during the period. Renaissance Technologies LLC increased its holdings in Cellebrite DI by 14.7% in the 1st quarter. Renaissance Technologies LLC now owns 2,860,639 shares of the company’s stock valued at $39,420,000 after purchasing an additional 365,700 shares during the last quarter. Weiss Asset Management LP increased its holdings in Cellebrite DI by 3,485.3% in the 1st quarter. Weiss Asset Management LP now owns 1,899,841 shares of the company’s stock valued at $26,180,000 after purchasing an additional 1,846,851 shares during the last quarter. Finally, Ashford Capital Management Inc. raised its position in Cellebrite DI by 5.5% in the first quarter. Ashford Capital Management Inc. now owns 1,762,937 shares of the company’s stock valued at $24,293,000 after purchasing an additional 92,092 shares during the period. 45.88% of the stock is owned by hedge funds and other institutional investors.
Cellebrite DI Company Profile
Cellebrite DI Ltd. develops digital intelligence software and services that help organizations access, collect, preserve and analyze digital evidence. Its tools are used to investigate information from mobile devices, computers, cloud sources and other digital systems. The company’s offerings include its UFED platform for extracting data from digital devices, Physical Analyzer for examining and interpreting evidence, and analytics and case-management tools such as Pathfinder and Guardian. Customers include law enforcement, public safety, intelligence and defense agencies, as well as organizations in the private sector.
Recommended Stories
- Five stocks we like better than Cellebrite DI
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.
